| HOME >> MEDICINE >> TECHNOLOGY |
Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:
Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8811In the United States:
Cindy Zheng
Brunswick Group
Tel: 1-212-333-3810In Beijing:
Yue Yu
Brunswick Group
Tel: 86-10-5960-8600 In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000 Simcere Pharmaceutical GroupPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME(Amounts expressed IN THOUSANDS, EXCEPT SHARE AND ADS DATA)Three months ended September 30,Nine months ended September 30,201020112011201020112011RMBRMBUSDRMBRMBUSDProduct revenue
541,971
500,962
78,5451,538,609
1,529,527
239,813Other revenue
8,157
-
-14,756
-
-Total revenue550,128500,96278,5451,553,3651,529,527239,813Cost of materials and production
(83,348)
(77,311)
(12,121)(248,543)
(237,545)
(37,244)Gross profit466,780423,65166,4241,304,8221,291,982202,569Operating income (expenses):Research and development
(32,502)
(45,410)
(7,120)(94,289)
(128,139)
(20,091)Sales, marketing and distribution
(298,712)
(291,296)
(45,672)(855,536)
(844,546)
(132,416)General and administrative
(74,015)
(69,562)
(10,907)(199,895)
(212,360)
(33,296)Other operating income *
-15,000
2,352-35,000
5,488Income from operations61,55132,3835,077155,102141,93722,254Interest income
842
1,278
2003,204
3,640
571Interest expense
(5,438)
(11,903)
(1,866)(14,455)
(31,308)
'/>"/>
| SOURCE Simcere Pharmaceutical Group Copyright©2010 PR Newswire. All rights reserved |